Global Solid Tumors Drugs Market Size, Status, Research and Forecast 2019-2025

Published On: Jul 2019

Format: PDF

Publisher: QY Research

Pages: 106

Report ID: 3458

Solid tumors are an abnormal mass of tissue that do not contain cysts or liquid areas. These may be malignant (cancerous) or benign (not cancerous). They affect bones, organs, and muscles. Based on the type of the cells, solid tumors can be carcinomas, sarcomas, and lymphomas.
During 2017, the biologics segment dominated the market and accounted for close to 55% of the market share in terms of revenue. This segment consists of medicinal products extracted from biological sources such as human, animal, microorganisms, or they are manufactured using the latest, cutting-edge biotechnological processes. Biologics include products such as enzymes, blood and blood components, gene therapy, recombinant proteins, somatic cells, tissues, and vaccines.
In terms of geography, the Americas dominated the global solid tumors drugs market. The growth of this market in the Americas is attributed to the increasing uptake of existing biologics drugs and the launch of new biologics. However, the revenue from these drugs will decrease during the forecast period because of the loss of patent exclusivity of drugs, leading to the entry of generics. This decline is expected to be partially offset by favorable reimbursement plans by the government, such as the provision of Medicare and Medicaid. The US is the largest revenue contributor in this region.
In 2018, the global Solid Tumors Drugs market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Solid Tumors Drugs status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Solid Tumors Drugs development in United States, Europe and China.

The key players covered in this study
Hoffmann-La Roche
Novartis
Celgene
Johnson & Johnson
Pfizer
BMS
Eli Lilly
GSK
Merck
Sanofi
AbbVie
AstraZeneca
Bayer
Biogen
Boehringer Ingelheim
Boston Biomedical
Daiichi Sankyo

Market segment by Type, the product can be split into
Small Molecules
Biologics

Market segment by Application, split into
Hospitals
Clinics
Academic and Research Institutes

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Solid Tumors Drugs status, future forecast, growth opportunity, key market and key players.
To present the Solid Tumors Drugs development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Solid Tumors Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Solid Tumors Drugs Market Size Growth Rate by Type (2014-2025)
1.4.2 Small Molecules
1.4.3 Biologics
1.5 Market by Application
1.5.1 Global Solid Tumors Drugs Market Share by Application (2014-2025)
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Academic and Research Institutes
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Solid Tumors Drugs Market Size
2.2 Solid Tumors Drugs Growth Trends by Regions
2.2.1 Solid Tumors Drugs Market Size by Regions (2014-2025)
2.2.2 Solid Tumors Drugs Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 Solid Tumors Drugs Market Size by Manufacturers
3.1.1 Global Solid Tumors Drugs Revenue by Manufacturers (2014-2019)
3.1.2 Global Solid Tumors Drugs Revenue Market Share by Manufacturers (2014-2019)
3.1.3 Global Solid Tumors Drugs Market Concentration Ratio (CR5 and HHI)
3.2 Solid Tumors Drugs Key Players Head office and Area Served
3.3 Key Players Solid Tumors Drugs Product/Solution/Service
3.4 Date of Enter into Solid Tumors Drugs Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Solid Tumors Drugs Market Size by Type (2014-2019)
4.2 Global Solid Tumors Drugs Market Size by Application (2014-2019)

5 United States
5.1 United States Solid Tumors Drugs Market Size (2014-2019)
5.2 Solid Tumors Drugs Key Players in United States
5.3 United States Solid Tumors Drugs Market Size by Type
5.4 United States Solid Tumors Drugs Market Size by Application

6 Europe
6.1 Europe Solid Tumors Drugs Market Size (2014-2019)
6.2 Solid Tumors Drugs Key Players in Europe
6.3 Europe Solid Tumors Drugs Market Size by Type
6.4 Europe Solid Tumors Drugs Market Size by Application

7 China
7.1 China Solid Tumors Drugs Market Size (2014-2019)
7.2 Solid Tumors Drugs Key Players in China
7.3 China Solid Tumors Drugs Market Size by Type
7.4 China Solid Tumors Drugs Market Size by Application

8 Japan
8.1 Japan Solid Tumors Drugs Market Size (2014-2019)
8.2 Solid Tumors Drugs Key Players in Japan
8.3 Japan Solid Tumors Drugs Market Size by Type
8.4 Japan Solid Tumors Drugs Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Solid Tumors Drugs Market Size (2014-2019)
9.2 Solid Tumors Drugs Key Players in Southeast Asia
9.3 Southeast Asia Solid Tumors Drugs Market Size by Type
9.4 Southeast Asia Solid Tumors Drugs Market Size by Application

10 India
10.1 India Solid Tumors Drugs Market Size (2014-2019)
10.2 Solid Tumors Drugs Key Players in India
10.3 India Solid Tumors Drugs Market Size by Type
10.4 India Solid Tumors Drugs Market Size by Application

11 Central & South America
11.1 Central & South America Solid Tumors Drugs Market Size (2014-2019)
11.2 Solid Tumors Drugs Key Players in Central & South America
11.3 Central & South America Solid Tumors Drugs Market Size by Type
11.4 Central & South America Solid Tumors Drugs Market Size by Application

12 International Players Profiles
12.1 Hoffmann-La Roche
12.1.1 Hoffmann-La Roche Company Details
12.1.2 Company Description and Business Overview
12.1.3 Solid Tumors Drugs Introduction
12.1.4 Hoffmann-La Roche Revenue in Solid Tumors Drugs Business (2014-2019)
12.1.5 Hoffmann-La Roche Recent Development
12.2 Novartis
12.2.1 Novartis Company Details
12.2.2 Company Description and Business Overview
12.2.3 Solid Tumors Drugs Introduction
12.2.4 Novartis Revenue in Solid Tumors Drugs Business (2014-2019)
12.2.5 Novartis Recent Development
12.3 Celgene
12.3.1 Celgene Company Details
12.3.2 Company Description and Business Overview
12.3.3 Solid Tumors Drugs Introduction
12.3.4 Celgene Revenue in Solid Tumors Drugs Business (2014-2019)
12.3.5 Celgene Recent Development
12.4 Johnson & Johnson
12.4.1 Johnson & Johnson Company Details
12.4.2 Company Description and Business Overview
12.4.3 Solid Tumors Drugs Introduction
12.4.4 Johnson & Johnson Revenue in Solid Tumors Drugs Business (2014-2019)
12.4.5 Johnson & Johnson Recent Development
12.5 Pfizer
12.5.1 Pfizer Company Details
12.5.2 Company Description and Business Overview
12.5.3 Solid Tumors Drugs Introduction
12.5.4 Pfizer Revenue in Solid Tumors Drugs Business (2014-2019)
12.5.5 Pfizer Recent Development
12.6 BMS
12.6.1 BMS Company Details
12.6.2 Company Description and Business Overview
12.6.3 Solid Tumors Drugs Introduction
12.6.4 BMS Revenue in Solid Tumors Drugs Business (2014-2019)
12.6.5 BMS Recent Development
12.7 Eli Lilly
12.7.1 Eli Lilly Company Details
12.7.2 Company Description and Business Overview
12.7.3 Solid Tumors Drugs Introduction
12.7.4 Eli Lilly Revenue in Solid Tumors Drugs Business (2014-2019)
12.7.5 Eli Lilly Recent Development
12.8 GSK
12.8.1 GSK Company Details
12.8.2 Company Description and Business Overview
12.8.3 Solid Tumors Drugs Introduction
12.8.4 GSK Revenue in Solid Tumors Drugs Business (2014-2019)
12.8.5 GSK Recent Development
12.9 Merck
12.9.1 Merck Company Details
12.9.2 Company Description and Business Overview
12.9.3 Solid Tumors Drugs Introduction
12.9.4 Merck Revenue in Solid Tumors Drugs Business (2014-2019)
12.9.5 Merck Recent Development
12.10 Sanofi
12.10.1 Sanofi Company Details
12.10.2 Company Description and Business Overview
12.10.3 Solid Tumors Drugs Introduction
12.10.4 Sanofi Revenue in Solid Tumors Drugs Business (2014-2019)
12.10.5 Sanofi Recent Development
12.11 AbbVie
12.12 AstraZeneca
12.13 Bayer
12.14 Biogen
12.15 Boehringer Ingelheim
12.16 Boston Biomedical
12.17 Daiichi Sankyo

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details